SAR-445877

N/A

Report date: 2026/05/13 14:32:48

Base Information

Drug NameSAR-445877
Drug Alias NameSAR-445877KD-050mut-1N-IL-15/38B2SAR-877
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionProgrammed cell death protein 1 blockersInterleukin-15 receptors agonists
TargetsProgrammed cell death protein 1Interleukin-15 receptors
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursCarcinoma, Non-Small-Cell Lung +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlandsChile +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesKadmon Corporation Llc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSanofiThe University Of Texas MD Anderson Cancer CenterSanofi (China) Investment Co Ltd
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursCarcinoma, Non-Small-Cell Lung +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A